NCT04002752

A Study of JNJ-73763989 in Healthy Japanese Adult Participants

A Double-blind, Placebo-controlled, Randomized, Parallel, Single Dose Study to Investigate Pharmacokinetics, Safety, and Tolerability of JNJ-73763989 in Healthy Japanese Adult Participants

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 25 (actual)
• Sponsor: Janssen Sciences Ireland UC · Industry
• Sex: All
• Age: 20 Years – 55 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to investigate the pharmacokinetics, safety, and tolerability of JNJ-73763989 in healthy Japanese adult participants following single-dose subcutaneous administration of 3 different doses of JNJ-73763989, Dose Level 1 (Panel A), Dose Level 2 (Panel B) or Dose Level 3 (Panel C).

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	JNJ-73763989	Participants will receive JNJ-73763989 as single subcutaneous injection.
DRUG	Placebo	Participants will receive placebo matching to JNJ-73763989 as single subcutaneous injection.

Timeline

• Start date: 2019-07-04
• Primary completion: 2019-08-23
• Completion: 2019-08-23
• First posted: 2019-07-01
• Last updated: 2025-02-03

Locations

1 site across 1 country: United Kingdom

Regulatory

• FDA-regulated drug study